MARINUS PHARMACEUTICALS, INC.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor, PA 19087
April 11, 2023
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tim Buchmiller
Re: | Marinus Pharmaceuticals, Inc. |
Registration Statement on Form S-3 | |
Filed March 31, 2023 | |
File No. 333-271041 | |
Request for Acceleration of Effective Date |
Dear Mr. Buchmiller:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on April 11, 2023, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.
Very truly yours, | ||
MARINUS PHARMACEUTICALS, INC. | ||
By: | /s/ Steven Pfanstiel | |
Name: | Steven Pfanstiel | |
Title: | Chief Financial Officer, Chief Operating Officer and Treasurer |